Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (Diluted Average) (2020 - 2026)

Viridian Therapeutics, Inc.\DE has reported Shares Outstanding (Diluted Average) over the past 7 years, most recently at $79620.0 for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) fell 99.9% year-over-year to $79620.0; the TTM value through Mar 2026 reached $79620.0, down 99.9%, while the annual FY2025 figure was $138875.0, 99.8% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $79620.0 at Viridian Therapeutics, Inc.\DE, down from $138875.0 in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $81.3 million in Q1 2025 and troughed at $33436.0 in Q4 2022.
  • A 5-year average of $32.6 million and a median of $33.7 million in 2022 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 38864.24% in 2024 and later tumbled 99.9% in 2026.
  • Year by year, Shares Outstanding (Diluted Average) stood at $33436.0 in 2022, then skyrocketed by 421.07% to $174226.0 in 2023, then skyrocketed by 38864.24% to $67.9 million in 2024, then crashed by 99.8% to $138875.0 in 2025, then tumbled by 42.67% to $79620.0 in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for VRDN at $79620.0 in Q1 2026, $138875.0 in Q4 2025, and $145160.0 in Q3 2025.